Sentinel lymph node biopsy using dye alone in patients with initial clinical N1 breast cancer receiving neoadjuvant therapy: A multicenter diagnostic trial (Northern Breast Cancer Collaboration Group NBCG‐002)
Single-dye SLNB after NAT in patients initially diagnosed with cN1 breast cancer yielded a clinically acceptable FNR. When four or more SLNs were identified, an additional benefit was observed in patients who had a BMI <25 kg/m<sup>2</sup> and negative estrogen receptor status.
Authors
- Jian‐Yun Nie (ORCID: https://orcid.org/0000-0003-1556-3335)
- Ang Zheng
- Yu Cao (ORCID: https://orcid.org/0000-0003-3708-575X)
- Fei Ma
- L. Zhang
- Jian‐yi Li
- Bo Chen (ORCID: https://orcid.org/0000-0002-2216-2794)
- Feng Jin (ORCID: https://orcid.org/0000-0002-4450-6084)
- Yi-Xiang Wang (ORCID: https://orcid.org/0000-0002-4021-4228)
- Dian‐Long Zhang
- Ai‐Ping Shi
- Fan Yao
- Bao‐Liang Guo
- Li Ma
- Pei‐Fen Fu
- Tian Zhang
Institutions
- Hebei Medical University (CN)
- Harbin Medical University (CN)
- Dalian Medical University (CN)
- Jilin University (CN)
- Kunming Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- First Hospital of Jilin University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- First Hospital of China Medical University (CN)
- Affiliated Zhongshan Hospital of Dalian University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- First Affiliated Hospital Zhejiang University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1002/cncr.70298
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Medical University